GlassScriptPhysician profile
Daphnie C Joseph
NPI 1942713201
$3,948.62
in general payments reported to CMS, 2019-2025
20 companies · $1,661 in 2025
The $1,661 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $137 · 2023: $723 · 2024: $1,427 · 2025: $1,661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,812.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,811.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $896.20 | 2023-2025 | |
| Gilead Sciences, INC. | $505.57 | 2024-2025 | Epclusa, Vemlidy |
| Intra-Sana Laboratories | $500.00 | 2023-2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $247.72 | 2023-2025 | Xifaxan |
| Argenx US, INC. | $240.12 | 2024 | Vyvgart Hytrulo |
| Cvrx, INC. | $147.20 | 2024 | Barostim Neo System |
| Abbott Laboratories | $142.12 | 2024 | Freestyle Libre 3 |
| Aimmune Therapeutics, INC. | $125.00 | 2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $124.97 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $124.97 | 2022 | |
| Kyowa Kirin, INC. | $121.83 | 2025 | |
| Novo Nordisk INC | $119.19 | 2025 | Wegovy |
| Exact Sciences Corporation | $116.36 | 2025 | The Cologuard Plus Collection Kit |
| Enterra Medical, INC. | $108.93 | 2025 | |
| Janssen Biotech, INC. | $107.64 | 2025 | Tremfya |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $104.17 | 2025 | Iqirvo |
| Ultragenyx Pharmaceutical INC. | $102.36 | 2024 | Dojolvi |
| Acadia Pharmaceuticals INC | $77.33 | 2024 | Nuplazid |
| Takeda Pharmaceuticals U.S.A., INC. | $25.03 | 2025 | Entyvio |
| Glaxosmithkline, LLC. | $11.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daphnie Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.